Company newsMRNA
Explain this story: TriSalus Secures FDA Clearance For TriNav Advance as Stock Tests Key Support
TriSalus Life Sciences Inc. received FDA 510(k) clearance for its TriNav Advance, an expansion of its Pressure-Enabled Drug Delivery (PEDD) platform for interventional oncology. Despite the clearance, the stock, trading as TLSI, saw a slight decline on Wednesday but maintains a constructive long-term technical outlook above key moving averages. The article highlights critical resistance at $6.00 and support at $4.50, noting the importance of breaking above the resistance for continued upward momentum.
OtherTradingViewSector and industry: HealthcareBiotechnologyTell me moreShow less
We have not explained this story yet. The original headline, summary and link are below.
TriSalus Life Sciences Inc. received FDA 510(k) clearance for its TriNav Advance, an expansion of its Pressure-Enabled Drug Delivery (PEDD) platform for interventional oncology. Despite the clearance, the stock, trading as TLSI, saw a slight decline on Wednesday but maintains a constructive long-term technical outlook above key moving averages. The article highlights critical resistance at $6.00 and support at $4.50, noting the importance of breaking above the resistance for continued upward momentum.
Article tone: Neutral This describes the words the journalist used. It is not a prediction, and not advice.
Also mentioned:MRNA
Published Sep 23, 2026, 16:20 ET · on this site +3d 9h